I am losing patients with the ASX with regard to bio and early medtech stocks. SGHT up 22% on reimbursement news applicable to EYE but EYE up 4%.
If we relisted in the US our MC would be $350m and the SP would be $1.50. If 2RT has a future why not list the glaucoma business and keep the AMD tech free carried for a later date. Keating once stated that Australia was a quarry and I am beginning to agree with him. The ASX presently does not deserve us.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-40
-
- There are more pages in this discussion • 468 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.3¢ |
Change
-0.003(1.61%) |
Mkt cap ! $34.93M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 15.0¢ | $7.963K | 52.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 304645 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 70717 | 5 |
View Market Depth
| Last trade - 15.57pm 18/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |